These data supported the initiation of a phase 3 clinical development program for tirzepatide, known as SURPASS (8), and in particular, the results reported from SURPASS-2, a 40-wk pivotal trial in subjects with T2DM, indicate the benefit of dual GIP/GLP-1 pharmacology (9). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.